

SUPPLEMENTAL FILES

Supplemental files are intended for publication as an online data supplement.

Supplemental Table 1. International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes

Diagnosis Category	ICD-10-CM Codes					
Nontraumatic hemorrhagic stroke	I60	I61	I62.0	I62.1	I62.9	-
Nontraumatic ischemic stroke	I63.0	I63.1	I63.2	I63.3	I63.4	I63.5
Atrial fibrillation	I48.0	I48.1	I48.2	I48.91	-	-

Supplemental Table 2. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies

	Item No	Recommendation	Complete
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	4-5
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	8-9
Objectives	3	State specific objectives, including any prespecified hypotheses	9-10
Methods			
Study design	4	Present key elements of study design early in the paper	10
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	11-13, Figure 1
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	10-11
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	11-12
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	10-13
Bias	9	Describe any efforts to address potential sources of bias	12-13
Study size	10	Explain how the study size was arrived at	11-13, Figure 1
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	10-13
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	12-13
		(b) Describe any methods used to examine subgroups and interactions	12-13
		(c) Explain how missing data were addressed	Figure 1
		(d) If applicable, describe analytical methods taking account of sampling strategy	N/A
		(e) Describe any sensitivity analyses	N/A
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	13-19 and Figure 1
		(b) Give reasons for non-participation at each stage	Figure 1
		(c) Consider use of a flow diagram	Figure 1

Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	13-15, Table 1
		(b) Indicate number of participants with missing data for each variable of interest	Figure 1
Outcome data	15*	Report numbers of outcome events or summary measures	13-19
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	13-19 and Tables 1–3
		(b) Report category boundaries when continuous variables were categorized	13-19 and Tables 1–3
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	-
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	18-19
Discussion			
Key results	18	Summarise key results with reference to study objectives	19-22
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	22-23
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	19-23
Generalisability	21	Discuss the generalisability (external validity) of the study results	23
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	N/A